Antithrombotic therapy in peripheral arterial disease.
The management of elderly patients with peripheral arterial disease requires a multidisciplinary and individualized approach, especially for patients requiring intervention and for those on antithrombotic therapy. Communication between the patient's primary physician, consulting medical specialists, and vascular surgeon is essential because all may contribute synergistically to deliver optimal care to the patient. This article reviews the pathophysiology of peripheral arterial disease, and data regarding the use of antiplatelet and anticoagulant agents.
Lipsitz
Evan C
EC
Vascular Diagnostic Laboratory Services, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA. elipsitz@aol.com
Kim
Soo
S
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015577:Geriatric Assessment; D006801:Humans; D008297:Male; D016491:Peripheral Vascular Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors